| NCT Number | NCT06903234 |
| Lead Sponsor | Novartis Pharmaceuticals |
| Conditions | Hemoglobinuria, Paroxysmal |
| Enrollment | 200 participants |
| Start Date | 2025-03-31 |
| Primary Completion | 2029-10-01 (estimated) |
| Study Completion | 2029-10-01 (estimated) |
| Updated on ClinicalTrials.gov | 2026-06-23 |